MENU
+Compare
RSLS
Stock ticker: NASDAQ
AS OF
Mar 10 closing price
Price
$0.73
Change
-$0.17 (-18.89%)
Capitalization
4.33M

RSLS ReShape Lifesciences Inc Forecast, Technical & Fundamental Analysis

Reshape Lifesciences Inc is a medical device company focused on technologies to treat obesity and metabolic diseases... Show more

RSLS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Ad is loading...
A.I.Advisor
a Summary for RSLS with price predictions
Mar 10, 2025

RSLS in -22.81% downward trend, sliding for three consecutive days on March 10, 2025

Moving lower for three straight days is viewed as a bearish sign. Keep an eye on this stock for future declines. Considering data from situations where RSLS declined for three days, in of 377 cases, the price declined further within the following month. The odds of a continued downward trend are .

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Aroon Indicator for RSLS entered a downward trend on March 10, 2025. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Bullish Trend Analysis

The RSI Indicator shows that the ticker has stayed in the oversold zone for 22 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an Uptrend is expected.

The Moving Average Convergence Divergence (MACD) for RSLS just turned positive on March 05, 2025. Looking at past instances where RSLS's MACD turned positive, the stock continued to rise in of 45 cases over the following month. The odds of a continued upward trend are .

RSLS may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.264) is normal, around the industry mean (23.616). P/E Ratio (0.000) is within average values for comparable stocks, (83.075). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (5.667). Dividend Yield (0.000) settles around the average of (0.018) among similar stocks. P/S Ratio (0.038) is also within normal values, averaging (41.506).

The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating slightly worse than average price growth. RSLS’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. RSLS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 90, placing this stock worse than average.

View a ticker or compare two or three
RSLS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Ad is loading...
A.I. Advisor
published General Information

General Information

a developer of medical devices for the treatment of obesity

Industry MedicalSpecialties

Profile
Fundamentals
Details
Industry
Medical Specialties
Address
1001 Calle Amanecer
Phone
+1 949 429-6680
Employees
40
Web
https://www.reshapelifesciences.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
UHS174.551.89
+1.09%
Universal Health Services
OGEN0.28N/A
+0.35%
Oragenics
TALO8.60-0.22
-2.49%
Talos Energy
CSTL18.92-1.29
-6.38%
Castle Biosciences
DHX1.82-0.33
-15.35%
DHI Group

RSLS and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, RSLS has been loosely correlated with GENE. These tickers have moved in lockstep 45% of the time. This A.I.-generated data suggests there is some statistical probability that if RSLS jumps, then GENE could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To RSLS
1D Price
Change %
RSLS100%
-18.83%
GENE - RSLS
45%
Loosely correlated
N/A
HSCS - RSLS
35%
Loosely correlated
-3.57%
GMED - RSLS
31%
Poorly correlated
-2.52%
AZTA - RSLS
30%
Poorly correlated
-0.41%
LFWD - RSLS
29%
Poorly correlated
-20.18%
More